The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is Annex 1C of the WTO Agreement. It establishes minimum standards for IP protection and enforcement that all WTO members must implement in their domestic laws. TRIPS fundamentally transformed the global IP landscape by linking IP to the multilateral trading system and providing enforceable dispute resolution.
Why: Before TRIPS, countries could join WIPO treaties but set minimal protection. Developed countries (especially the US, EU, Japan) demanded enforceable global IP standards to protect their knowledge-intensive exports. Developing countries accepted TRIPS as part of the WTO "single undertaking" in exchange for market access benefits in agriculture and textiles.
Legal Framework
| Element | Detail |
|---|---|
| Adopted | 15 April 1994 (Marrakesh) |
| Entered into force | 1 January 1995 |
| Part of | WTO Agreement (Annex 1C); single undertaking |
| Members | All 164 WTO members |
| Administered by | WTO TRIPS Council |
| Enforced by | WTO Dispute Settlement Body (DSB) |
| India's compliance deadline | 1 January 2005 (for product patents in all fields, including pharmaceuticals) |
Structure of TRIPS
| Part | Articles | Content |
|---|---|---|
| Part I | Art. 1-8 | General Provisions and Basic Principles |
| Part II | Art. 9-40 | Standards Concerning Availability, Scope, and Use of IP Rights |
| Part III | Art. 41-61 | Enforcement |
| Part IV | Art. 62 | Acquisition and Maintenance of IP Rights |
| Part V | Art. 63-64 | Dispute Prevention and Settlement |
| Part VI | Art. 65-67 | Transitional Arrangements |
| Part VII | Art. 68-73 | Institutional Arrangements, Final Provisions |
Key Substantive Provisions
Part I: General Provisions (Art. 1-8)
| Article | Principle | Content |
|---|---|---|
| Art. 1.1 | Minimum standards | Members may provide more extensive protection; must not contravene TRIPS |
| Art. 3 | National Treatment | No less favourable treatment for foreign nationals |
| Art. 4 | Most-Favoured-Nation | Advantage to one member's nationals must be extended to all |
| Art. 7 | Objectives | IP protection should contribute to promotion of innovation, transfer of technology, mutual advantage of producers and users, social and economic welfare, balance of rights and obligations |
| Art. 8 | Principles | Members may adopt measures for public health, nutrition, public interest, prevention of abuse of IP rights |
Part II: Standards by Category
| Category | Articles | Key requirements |
|---|---|---|
| Copyright | Art. 9-14 | Berne Convention + computer programs as literary works + rental rights + performer/broadcaster protection |
| Trademarks | Art. 15-21 | Protectable subject matter, rights, well-known marks, term (minimum 7 years renewable), no compulsory licensing |
| Geographical Indications | Art. 22-24 | Protection against misleading use; additional protection for wines and spirits |
| Industrial Designs | Art. 25-26 | Minimum 10 years protection; textile design provisions |
| Patents | Art. 27-34 | All fields of technology; 20-year term; reversal of burden of proof for process patents |
| Layout Designs (ICs) | Art. 35-38 | Incorporates Washington Treaty; 10 years protection |
| Undisclosed Information | Art. 39 | Trade secrets; test data protection |
| Anti-competitive practices | Art. 40 | Permits control of anti-competitive IP licensing |
Patent provisions (Art. 27-34): Most significant for India
| Provision | Requirement | India's response |
|---|---|---|
| Art. 27.1 | Patents available in all fields of technology without discrimination | Introduced product patents for pharmaceuticals (2005 Amendment) |
| Art. 27.1 | Non-discrimination between imported and locally produced products | Amended working requirements |
| Art. 28 | Rights: making, using, selling, importing | S.48, Patents Act |
| Art. 29 | Disclosure: sufficiently clear and complete | S.10, Patents Act |
| Art. 31 | Compulsory licensing: conditions | S.84-92, Patents Act (with additional conditions) |
| Art. 33 | Minimum 20 years from filing | S.53, Patents Act (amended from 14 to 20 years) |
| Art. 34 | Process patent: burden of proof reversal | S.104A, Patents Act |
Impact of TRIPS on India
Legislative changes
| Year | Amendment | TRIPS compliance |
|---|---|---|
| 1999 | Patents (Amendment) Act, 1999 | Mailbox provision + Exclusive Marketing Rights (EMR) for pharma (Art. 70.8-70.9) |
| 2002 | Patents (Amendment) Act, 2002 | 20-year term; international exhaustion; compulsory licence conditions |
| 2005 | Patents (Amendment) Act, 2005 | Product patents for food, chemicals, pharmaceuticals; S.3(d) anti-evergreening |
| 1999 | Trade Marks Act, 1999 | Replaced 1958 Act; service marks, well-known marks, appellate board |
| 1999 | GI Act, 1999 | New statute to comply with TRIPS Art. 22-24 |
| 2000 | Designs Act, 2000 | Replaced 1911 Act; increased term to 15 years |
| 2000 | SICLD Act, 2000 | Sui generis IC layout protection (TRIPS Art. 35-38) |
| 2012 | Copyright (Amendment) Act, 2012 | Digital rights, performer rights, statutory licensing |
TRIPS Flexibilities used by India
| Flexibility | TRIPS basis | Indian implementation |
|---|---|---|
| S.3(d) | Art. 27.1 (patentable subject matter defined by members) | Excludes new forms of known substances without enhanced efficacy |
| Compulsory licensing | Art. 31 | S.84 (after 3 years); S.92 (national emergency); Natco v. Bayer (2012) |
| Parallel imports | Art. 6 (exhaustion left to members) | S.107A: importation of patented product legitimately sold abroad |
| Bolar exception | Art. 30 (limited exceptions) | S.107A(a): acts for obtaining regulatory approval before patent expiry |
| Pre-grant opposition | Not prohibited | S.25(1): any person may oppose before grant |
| Post-grant opposition | Not prohibited | S.25(2): any interested person may oppose after grant |
Doha Declaration on TRIPS and Public Health (2001)
| Paragraph | Content |
|---|---|
| Para 4 | TRIPS should be interpreted and implemented to support members' right to protect public health and promote access to medicines |
| Para 5(b) | Each member has the right to grant compulsory licences and freedom to determine grounds |
| Para 5(c) | Each member has freedom to establish its own regime of exhaustion (parallel imports) |
| Para 6 | Members with insufficient manufacturing capacity can import under compulsory licence from other members |
Why: Doha Declaration was political recognition that TRIPS flexibilities are real and must not be undermined by TRIPS-plus bilateral pressure. India's S.3(d) and compulsory licensing regime are consistent with Doha.
Illustrations
-
TRIPS changed India's pharma landscape: Before 2005: Indian companies like Cipla, Ranbaxy could legally copy any drug (only process patents existed). They'd reverse-engineer the molecule and manufacture using a different process. India became "pharmacy of the developing world." After 2005: Product patents mean Cipla CANNOT manufacture a patented molecule by ANY process without licence. The molecule itself is protected. This is why compulsory licensing (S.84) and S.3(d) became India's critical safety valves.
-
WTO enforcement vs old WIPO (the teeth difference): Under Berne Convention alone: Country A violates copyright obligations. Country B complains to WIPO. WIPO writes a letter. Country A ignores it. Nothing happens. Under TRIPS: Country A violates obligations. Country B files at WTO DSB. Panel rules against A. If A doesn't comply within reasonable period, B gets authorised to impose trade sanctions (e.g., raise tariffs on A's exports). A loses market access. THIS is why TRIPS works — it has economic teeth.
-
Doha Declaration in practice (COVID vaccines): During COVID-19, India and South Africa proposed a TRIPS waiver for vaccine patents. The argument: Doha Para 4 says TRIPS should support "right to protect public health." WTO eventually agreed to a partial waiver (June 2022) allowing developing countries to produce patented vaccines without consent for 5 years. This is Doha in action — political declaration becoming operational policy.
Recall Check
- What makes TRIPS different from all prior IP treaties in terms of enforcement?
- List the key legislative changes India made between 1999-2005 to comply with TRIPS.
- How does S.3(d) of the Indian Patents Act utilise TRIPS flexibility, and what did Doha Declaration affirm?
Key Cases
Novartis AG v. Union of India (2013) Novartis-AG-v-Union-of-India-2013 Issue: Whether S.3(d) of the Patents Act (barring patents on new forms of known substances without enhanced efficacy) violates TRIPS Art. 27. Rule: TRIPS Art. 27.1 requires patents for inventions in all fields, but "invention" is defined by national law; S.3(d) defines what constitutes a patentable invention in India. Held: S.3(d) is TRIPS-compliant. India has sovereign right to define patentability thresholds. TRIPS does not mandate patenting trivial modifications. Public health access can be balanced with IP through legitimate exclusions.
India - Patent Protection for Pharmaceuticals (WTO DS 79, 1998) India-Patent-Protection-Pharmaceuticals-WTO-1998 Issue: Whether India failed to implement TRIPS Art. 70.8 (mailbox) and Art. 70.9 (exclusive marketing rights). Rule: TRIPS transitional provisions required developing countries to establish a system for filing pharmaceutical patent applications during transition and granting EMRs pending examination. Held: India violated TRIPS by failing to establish an adequate mailbox system. India subsequently enacted Patents (Amendment) Act, 1999. Case demonstrated WTO's enforcement power over IP.
Natco Pharma v. Bayer (Controller of Patents, 2012) Natco-Pharma-v-Bayer-2012 Issue: Whether compulsory licence should be granted for Bayer's patented anti-cancer drug Nexavar (sorafenib tosylate). Rule: S.84(1): compulsory licence may be granted if (a) reasonable requirements of public not satisfied, (b) not available at reasonably affordable price, (c) not worked in territory of India. Held: India's first compulsory licence granted. Bayer's drug priced at Rs.2,80,000/month; Natco to sell at Rs.8,800/month. TRIPS Art. 31 conditions satisfied. Demonstrates TRIPS flexibility in action.
Distinctions
| Parameter | TRIPS | Paris/Berne Conventions |
|---|---|---|
| Coverage | All IP categories in one instrument | Paris: industrial property only; Berne: copyright only |
| Enforcement | WTO DSB (binding, sanctions) | No binding dispute mechanism |
| MFN | Yes (Art. 4) | Not present |
| Minimum standards | Prescriptive (20-year patents, life+50 copyright) | Flexible; leaves details to members |
| Trade linkage | Integral part of WTO system | No trade conditionality |
| Transition periods | Yes (Art. 65-66): developing 5 years, LDCs 11+ years | No transition provisions |
| Flexibilities | Art. 7-8, 30, 31, 6 | Implicit only |
Flashcards
Q: What is TRIPS and when did it enter into force? A: Agreement on Trade-Related Aspects of Intellectual Property Rights; Annex 1C of WTO Agreement; entered into force 1 January 1995.
Q: What is the "single undertaking" principle in WTO context? A: Countries cannot selectively join WTO agreements; acceptance of WTO membership requires acceptance of all agreements including TRIPS.
Q: What minimum patent term does TRIPS require? A: 20 years from the date of filing (Art. 33).
Q: What was India's first compulsory licence case and what was the outcome? A: Natco Pharma v. Bayer (2012); compulsory licence granted for Nexavar (sorafenib tosylate); price reduced from Rs.2,80,000 to Rs.8,800 per month.
Q: What does TRIPS Art. 27.1 require regarding patentable subject matter? A: Patents must be available for inventions in all fields of technology, whether products or processes, without discrimination as to place of invention, field of technology, or whether products are imported or locally produced.
Q: What is the Doha Declaration's significance for India? A: It affirmed that TRIPS flexibilities (compulsory licensing, parallel imports, defining patentable subject matter) are legitimate tools for public health; India's S.3(d) and CL regime are consistent with Doha.
Q: Name three TRIPS flexibilities India has utilised. A: S.3(d) (anti-evergreening), compulsory licensing (Natco v. Bayer 2012), parallel imports (S.107A), pre-grant and post-grant opposition (S.25).
Q: What did WTO DS 79 (1998) establish about India? A: India violated TRIPS by failing to establish a mailbox system for pharmaceutical patent applications during the transition period; demonstrated TRIPS is enforceable through WTO dispute settlement.
Exam Scenario
PharmaCorp (USA) holds a patent for Drug Z in India, expiring in 2030. The drug costs Rs.50,000/month. GenMed (India) applies for a compulsory licence under S.84 in 2027. PharmaCorp argues that: (a) Compulsory licensing violates TRIPS Art. 28 (exclusive rights of patentee); (b) India's S.3(d) is inconsistent with TRIPS Art. 27.1 (non-discrimination); and (c) Doha Declaration is merely political and has no legal force.
Advise: (i) The conditions GenMed must satisfy under S.84(1); (ii) Whether TRIPS Art. 31 permits compulsory licensing and under what conditions; (iii) The legal status of Doha Declaration and its interpretive role; (iv) Whether PharmaCorp can challenge India's patent law before WTO DSB. Refer to Novartis v. Union of India (2013) and Natco v. Bayer (2012).
See Also
- PIL-3.5 Treaties — TRIPS is a multilateral treaty; interpretation follows VCLT Art. 31; Doha Declaration is a subsequent agreement under VCLT Art. 31(3)(a)
- PIL-5.2 United Nations — WTO relationship with UN system; DSB enforcement mechanism distinguished from WIPO's non-binding dispute resolution
- PIL-5.4 Specialised Agencies of the United Nations — WIPO-WTO relationship: why two bodies govern international IP
- IoS-2.3 Mischief Rule — Indian courts apply mischief rule to interpret TRIPS-implementing provisions (e.g., S.3(d) Patents Act interpreted using Heydon's rule to identify mischief of evergreening)